RESUMEN
Since most sudden cardiac death victims show neither symptoms before the event nor other signs or risk factors that would have identified them as a high risk population before their cardiac arrest, emergency out-of-hospital medical services must be improved in order to obtain a higher survival in these patients. Early defibrillation is an essential part of the chain of survival that also includes the early identification of the victim, activation of the emergency medical system, immediate arrival of trained personnel who can perform basic cardiopulmonary resuscitation and early initiation of advanced cardiac life support that would raise the survival rate for sudden cardiac arrest victims. Many studies have demonstrated the enormous importance of early defibrillation in patients with a cardiac arrest due to ventricular fibrillation. The most important predictor of survival in these individuals is the time that elapses until electric defibrillation, the longer the time to defbrillation the lower the number of patients who are eventually discharged. Multiple studies have demonstrated that automatic external defibrillation will reduce the time elapsed to defibrillation and thus improve survival. For these reason, public access defibrillation to allow the use of automatic external defibrillators by minimally trained members of the lay public, has received increasing interest on the part of a groving number of companies, cities or countries. The automatic external defibrillaton, as performed by a lay person is being investigated. The liberalization of its application, if is demonstrated to be effective, will need to be accompanied by legal measures to endorse it and appropriate health education, probably during secondary education.
Asunto(s)
Muerte Súbita Cardíaca , Desfibriladores Implantables , Reanimación Cardiopulmonar , Análisis Costo-Beneficio , Urgencias Médicas , Humanos , Legislación MédicaRESUMEN
In the present paper, a historical review and a clinical up-date are done on two procedures of great medical interest: Holter electrocardiography and ambulatory blood pressure monitoring. Technical and methodological characteristics of each procedure are carefully exposed, emphasizing each the lack of an international agreement in order to establish regulations that make all the equipment homogeneous and reliable in order to increase both accuracy and reliability in diagnosis. Based on published international scientific documents and the personal experience of the authors, guidelines for clinical applications, indications and limitations of each technique are analyzed in relation to capacities of the Spanish political and social public health system profile. New concepts and dynamics of developments such as; dynamic QT, RR variability or pulse wave velocity are exposed, in the frame of the present time and future for improving efficiency and clinical application.
Asunto(s)
Monitoreo Ambulatorio de la Presión Arterial , Electrocardiografía Ambulatoria , Monitoreo Ambulatorio de la Presión Arterial/normas , Electrocardiografía Ambulatoria/normas , HumanosRESUMEN
Most of the prognostic information on patients with unstable angina is obtained from the initial clinical assessment and the patient's subsequent course over the first few days of management. In recently stabilized patients noninvasive stress testing with exercise or pharmacologic testing provide additional useful risk assessment. Noninvasive stress testing should be part of the outpatient evaluation of low-risk patients with unstable angina and should be done within 72 hours. Unless cardiac catheterization is indicated, noninvasive stress testing should be performed in low- or intermediate-risk patients hospitalized with unstable angina who have been free of symptoms for a minimum of 48 hours. Choice of stress testing modality should be based on an evaluation of the patient's resting ECG, his or her physical ability to perform exercise, and the local expertise and technologies available. The standard ECG treadmill test should be the standard test employed in most patients with no contraindications for doing so. Provocation of ischemia at a low workload (< 5 to 6 METs) signifies a high-risk patient (cardiac mortality > or = 4%/year) who should generally merit referral to cardiac catheterization. Attainment of a higher workload (> 5 to 6 METs) without ischemia is associated with a better prognosis (cardiac mortality < 1%/year), and many such patients can be managed conservatively. Those who tolerate only a low workload but have no evident ischemia or those who develop ischemia at a high workload, represent an intermediate-risk group (cardiac mortality 2 to 3%/year) for whom several reasonable strategies can be proposed.
Asunto(s)
Angina Inestable/diagnóstico , Prueba de Esfuerzo , Enfermedad Aguda , Angina Inestable/tratamiento farmacológico , Angina Inestable/etiología , Angina Inestable/fisiopatología , Ecocardiografía , Electrocardiografía , Humanos , Pronóstico , Medición de Riesgo , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
A randomized open-label clinical trial was conducted to determine whether mortality, readmission, or quality of life differed between heart failure patients managed with captopril plus diuretics and those with digoxin plus diuretics. A total of 345 heart failure patients in New York Heart Association functional classes 2 and 3 without atrial fibrillation, dyspnea of bronchopulmonary origin, or hypertension not controlled with diuretics was randomized for digoxin (n = 175) or captopril (n = 170) treatment and followed up for a median of 4.5 years. Socioeconomic, demographic, electrocardiographic, echocardiographic, spirometric, and chest radiograph data were obtained at the initial examination. In a random sample of half the patients, ergometric, echocardiographic, and Holter records were obtained at entry and at 3 and 18 months. Patients were followed up for > or = 3 years. The end points were mortality, hospitalization for cardiac events, deterioration in quality of life, worsening of functional class, and need for digoxin or captopril in the captopril and digoxin groups, respectively. The trial had to be terminated prematurely owing to the difficulty in finding candidates free of angiotensin-converting enzyme (ACE)-inhibitor treatment. Baseline patient characteristics were similar in both groups. From the clinical point of view, only the 48-month mortality was relevantly lower (20.9 vs. 31.9%, respectively) among patients treated with captopril than that in those receiving digoxin (log rank test, p = 0.07). No statistically or clinically relevant differences were found in other end points or adverse effects. The results suggest but do not confirm the hypothesis that captopril treatment in mild to moderate heart failure might provide better long-term survival than digoxin.
Asunto(s)
Gasto Cardíaco Bajo/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Captopril/efectos adversos , Captopril/uso terapéutico , Gasto Cardíaco Bajo/diagnóstico por imagen , Gasto Cardíaco Bajo/mortalidad , Gasto Cardíaco Bajo/fisiopatología , Cardiotónicos/efectos adversos , Cardiotónicos/uso terapéutico , Digoxina/efectos adversos , Digoxina/uso terapéutico , Diuréticos/efectos adversos , Diuréticos/uso terapéutico , Quimioterapia Combinada , Prueba de Esfuerzo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , España , Análisis de Supervivencia , UltrasonografíaRESUMEN
Since the first implantation in man in 1980 implantable cardioverter defibrillator technology has greatly improved and the number of devices implanted has increased considerably every year. Non thoracotomy lead systems and biphasic shocks are now the approach of choice, offering an almost 100% success rate. This document reviews the recommendations for qualification of personnel and for the centres implanting and carrying out follow-ups on defibrillators. The current indications for the implantation of implantable cardioverter defibrillator are also addressed.
Asunto(s)
Desfibriladores Implantables/normas , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/terapia , Cardiología , Muerte Súbita Cardíaca/prevención & control , Estudios de Seguimiento , Humanos , Calidad de Vida , Factores de Riesgo , EspañaRESUMEN
Many epidemiological studies have shown that moderate alcohol intake, from 10 to 30 g of ethanol a day, decreases cardiovascular mortality from atherosclerotic ischaemic heart disease and ischaemic stroke as compared to non-drinkers. This beneficial effect outweighs the risks of alcohol consumption in subgroups of people with a higher risk of atherosclerosis: the elderly, people with coronary risk factors and patients with previous coronary events. It has not been demonstrated that alcohol intake, even in moderate amounts, is beneficial for the general population, in particular, men under the age of 40 and women under 50, because it raises mortality due to other causes, especially injury, cirrhosis of the liver and some types of cancer, thereby outweighing the benefits for coronary artery disease. Thus, alcohol consumption should not be recommended as a prophylaxis for the general population. Guidelines on alcohol drinking habits--whether to continue, to start, to modify or to stop--must be given on an individual basis, taking into account the relative risks and benefits for each patient. The benefits of moderate alcohol consumption on the cardiovascular system seem to be exerted fundamentally through its effects on plasma lipoproteins, principally by raising high density lipoprotein (HDL) cholesterol and to a lesser degree, by decreasing low density lipoprotein (LDL) cholesterol. It appears to exert additional beneficial effects on the heart by decreasing platelet aggregability and by bringing about changes in the clotting-fibrinolysis system. Although there has been some debate about the relative superiority of different types of alcoholic beverages (wine, beer or hard liquor), and to a greater extent, about different types of wine, there is no current evidence of any kind of beneficial effect from other components of the beverage besides ethanol. Thus, it does not seem appropriate to recommend any particular type of alcoholic drink, except for sociocultural reasons. The added benefits from some components of different types of wine with a high antioxidant activity on plasma lipoproteins remain only an interesting hypothesis. Meanwhile, encouraging a healthy diet, flavonoid rich and with a predominance of natural ingredients (fruit, legumes, cereals and seeds), in the general population should stop the current tendency of Southern European countries from abandoning the Mediterranean diet. Because of the multifactorial nature of coronary heart disease, it is necessary to remember that atherosclerotic risk reduction is achieved by behavior modification of multiple risk factors present in individual patients and in the general population. Therefore, guidelines regarding alcohol intake should always be linked to pertinent recommendations about other atherosclerotic risk factors.
Asunto(s)
Enfermedad Coronaria/prevención & control , Vino , Consumo de Bebidas Alcohólicas , Bebidas Alcohólicas , Antioxidantes/metabolismo , Etanol/metabolismo , Etanol/farmacología , Femenino , Humanos , Lípidos/sangre , Masculino , Agregación Plaquetaria/efectos de los fármacos , Medición de RiesgoAsunto(s)
Isquemia Miocárdica/terapia , Antagonistas Adrenérgicos beta/uso terapéutico , Angina de Pecho/diagnóstico , Angina de Pecho/tratamiento farmacológico , Angina Inestable/diagnóstico , Angina Inestable/tratamiento farmacológico , Atenolol/uso terapéutico , Bisoprolol/uso terapéutico , Bloqueadores de los Canales de Calcio/uso terapéutico , Ensayos Clínicos como Asunto , Electrocardiografía , Electrocardiografía Ambulatoria , Prueba de Esfuerzo , Humanos , Estudios Multicéntricos como Asunto , Infarto del Miocardio/complicaciones , Isquemia Miocárdica/diagnóstico , Isquemia Miocárdica/tratamiento farmacológico , Revascularización Miocárdica , Nifedipino/uso terapéutico , Pronóstico , Simpaticolíticos/uso terapéuticoRESUMEN
Diagnosis and risk stratification in angina pectoris is supported on clinical evaluation, rest electrocardiogram, exercise stress test and coronary angiography. Use and timing application of that diagnostic methods depend on coronary artery disease prevalence and on clinical situation. This review describe diagnostic and prognostic value of the tests in angina pectoris.
Asunto(s)
Angina de Pecho/diagnóstico , Cardiología , Pruebas de Función Cardíaca/métodos , Humanos , Isquemia Miocárdica/diagnóstico , Pronóstico , Factores de Riesgo , Sociedades Médicas , EspañaAsunto(s)
Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Animales , Bloqueadores de los Canales de Calcio/uso terapéutico , Ensayos Clínicos como Asunto , Angiografía Coronaria , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Enfermedad de la Arteria Coronaria/etiología , Enfermedad de la Arteria Coronaria/patología , Humanos , Lípidos/sangre , Factores de RiesgoRESUMEN
We have performed 2 implantations of transvenous automatic cardioverter defibrillator in a cardiac laboratory devoted to electrophysiology and pacemaker implantation. This is a preliminary experience with a novel implant strategy. Cardiologists were the primary operators. The automatic cardioverter defibrillator were placed in a subcutaneous pectoral region, with a non-thoracotomy lead system. The automatic cardioverter defibrillator were two Medtronic 7219D PCD Jewel, with a Transvene system. There were no perioperative complications. Acceptable defibrillation threshold were obtained in both patients, 12 and 20 J, respectively. Leads were inserted percutaneously through the left subclavian vein. After 8 months of follow-up the patients continue to tolerate the device satisfactorily. Implantation of automatic cardioverter defibrillator systems by trained cardiologists in an electrophysiology laboratory is safe and feasible. Moreover, its cost-effectiveness is superior, the saving includes the surgeons, and the reduction of stay in unit of intensive care and hospitalization.
Asunto(s)
Desfibriladores Implantables , Electrofisiología , Estudios de Seguimiento , Humanos , Laboratorios de Hospital , Masculino , Métodos , Persona de Mediana Edad , Músculos Pectorales/cirugía , España , Taquicardia Ventricular/terapia , Fibrilación Ventricular/terapiaRESUMEN
UNLABELLED: INTRODUCTION AND PURPOSES: Autonomic nervous system plays an important role in the pathogenesis of vasovagal/vasodepressor syncope and may also be assessed by the RR variability analysis. Head up tilt test (HUT) is a currently established tool to evaluate patients with neuromediated syncope. However, the relationship between heart rate variability and tilt induced syncope is not established. The purpose of this study was to assess the differences in heart rate variability among patients with syncope and negative or positive tilt test. METHODS: Fifty patients (mean age 33 +/- 17 years, 24 female, 26 male) with syncope underwent tilt test (20 min, 80 degrees tilt and 20 min more under isoproterenol infusion). Twenty-three patients have a negative tilt, the rest had a positive test. There were not significant differences in age or sex. Immediately after the HUT a 24-hour ambulatory electrocardiogram was performed (Marquette system 8000, 002A program). The parameters measured during Holter monitoring were: SDANN, SD, rMSSD, pNN50 and frequency analysis of heart rate spectrum (low frequency 0.04-0.15 Hz, high frequency 0.15-0.4 Hz and the relation low/high). No significant differences were detected in age and sex in patients with and without positive HUT. RESULTS: pNN50 and rMSSD were the best predictors of the results of tilt (p = 0.006). SDANN and SDNN were not useful parameter. The finding of a value of pNN50 > 25% (value significantly different between patients with HUT--and +) have a specificity for predicting a positive HUT of 82.6%, with a sensibility of 51.8%. Positive predictive value was 77%. As can be easily understood, if the cut value of pNN50 is lowered, its sensibility increased and the specificity. decreased. In the frequency analysis only the relation low/high (L/H) was significantly different between both populations. CONCLUSIONS: Heart rate variability is a useful tool in the evaluation of patients with vasovagal syncope, that may identify patients with chronically elevated vagal tone and thus may predict tilt test results.
Asunto(s)
Sistema Nervioso Autónomo/fisiopatología , Electrocardiografía Ambulatoria , Frecuencia Cardíaca , Síncope/fisiopatología , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síncope/diagnóstico , Síncope/etiología , Nervio Vago/fisiopatologíaRESUMEN
UNLABELLED: INTRODUCTION AND PURPOSES: Propafenone is an antiarrhythmic drug with well known electrophysiological effects. We performed this prospective non comparative study, in order to evaluate its efficacy and safety to terminate spontaneous episodes of monomorphic sustained ventricular tachycardia. METHODS: Thirty-two episodes of sustained monomorphic ventricular tachycardia in 32 consecutive patients were treated with intravenous propafenone. Twenty-five were male and 7 female, mean age of 62 +/- 12 years; 23 suffered chronic ischemic heart disease, 2 dilated cardiomyopathy, 1 arrhythmogenic dysplasia of the right ventricle and 6 no organic heart disease. Patients with overt heart failure, acute myocardial infarction or a systolic blood pressure less than 90 mmHg were excluded. The ventricular origin of the tachycardia was assessed by clinical and electrocardiographic criteria and by the presence of AV dissociation in intraesophageal recording. The dose of propafenone was 0.2 mg/kg/min until interruption of ventricular tachycardia, or maximal dose of 2.5 mg/kg in 10 min. RESULTS: In 23 episodes (72%) sinus rhythm was restored in less than 10 minutes (mean time and dose, 398 +/- 97 s and 95 +/- 42 mg, respectively). Two patients developed proarrhythmia with acceleration of the ventricular tachycardia. A significant decrease in blood pressure was noted in 6 patients. Presence of organic heart disease, advanced age and poor functional class were the best predictors of inefficacy to convert to sinus rhythm and of the presence of acute adverse effects (p < 0.05). CONCLUSIONS: Propafenone is an effective drug for the acute conversion of spontaneous monomorphic sustained ventricular tachycardia, especially in patients without organic heart disease. Age, functional class and presence of organic heart disease could predict the response to propafenone and the incidence of complications.
Asunto(s)
Propafenona/administración & dosificación , Taquicardia Ventricular/tratamiento farmacológico , Enfermedad Aguda , Anciano , Distribución de Chi-Cuadrado , Evaluación de Medicamentos , Electrocardiografía/efectos de los fármacos , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Propafenona/efectos adversos , Estudios Prospectivos , Taquicardia Ventricular/fisiopatología , Factores de TiempoAsunto(s)
Fármacos Cardiovasculares/uso terapéutico , Enfermedades Cardiovasculares/tratamiento farmacológico , Cardiotónicos/uso terapéutico , Ensayos Clínicos como Asunto , Análisis Costo-Beneficio , Fibrinolíticos/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Humanos , Hipertensión/tratamiento farmacológico , Hipertrofia Ventricular Izquierda/tratamiento farmacológico , SociologíaAsunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Fibrilación Atrial/complicaciones , Fibrilación Atrial/etiología , Fibrilación Atrial/mortalidad , Trastornos Cerebrovasculares/epidemiología , Trastornos Cerebrovasculares/etiología , Ensayos Clínicos como Asunto , Contraindicaciones , Humanos , Válvula Mitral , Pronóstico , Factores de RiesgoRESUMEN
PURPOSE: To assess the relationship between late potentials and spontaneous ventricular arrhythmias, organic heart disease, inducibility of arrhythmias at electrophysiological study and ejection fraction. METHODS: The population is comprised by 52 patients (41 men, 11 women with mean age 50 +/- 16 years) with spontaneous clinically documented ventricular tachycardia or ventricular fibrillation. An electrophysiological study was performed with conventional programmed stimulation. Within a week of the test a study of late potentials was also performed. RESULTS: Late potentials were documented in 73% of the patients with ventricular tachycardia and only in 17% of the patients with ventricular fibrillation. Sixty-eight percent of the patients with ischemic cardiopathy presented late potentials and in these, ventricular tachycardia was inducible in 93%. Only one from a group of 7 patients with ventricular arrhythmias and no organic heart disease, presented late potentials. In patients with late potentials, 84% have inducible ventricular tachycardia, but only 26% of patients without late potentials have inducible ventricular tachycardia. The incidence of late potentials was inversely correlated with left ventricular ejection fraction. CONCLUSION: The presence of late potentials was more frequent in patients with ventricular tachycardia than in patients with ventricular fibrillation. The presence of late potentials has a sensibility of 81.5% and a specificity of 78% to detect patients with inducible ventricular tachycardia.
Asunto(s)
Electrofisiología , Taquicardia Ventricular/fisiopatología , Fibrilación Ventricular/fisiopatología , Potenciales de Acción , Adulto , Electrocardiografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Sensibilidad y Especificidad , Volumen Sistólico/fisiología , Taquicardia Ventricular/diagnóstico , Fibrilación Ventricular/diagnósticoAsunto(s)
Enfermedades Cardiovasculares/tratamiento farmacológico , Terapia Trombolítica , Angina Inestable/tratamiento farmacológico , Angioplastia Coronaria con Balón , Contraindicaciones , Fibrinolíticos/administración & dosificación , Cardiopatías/tratamiento farmacológico , Prótesis Valvulares Cardíacas , Humanos , Infarto del Miocardio/complicaciones , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/economía , Infarto del Miocardio/mortalidad , Embolia Pulmonar/tratamiento farmacológico , Terapia Trombolítica/efectos adversos , Terapia Trombolítica/economía , Tromboflebitis/tratamiento farmacológico , Trombosis/tratamiento farmacológico , Factores de TiempoRESUMEN
In this prospective, controlled and randomized cross-over study we tried to establish the efficiency and safety of flecainide vs procainamide for the treatment of acute atrial fibrillation. Eighty patients (30 females, 50 males, mean age: 55 +/- 14 years) were included. Patients entered into the study if they had atrial fibrillation of recent onset (< 24 h) with a ventricular rate > 100 beats.min-1 at rest and were < 75 years of age. Exclusion criteria were any sign of heart failure, conduction disturbances, sick sinus syndrome or acute ischaemic events. Randomly 40 patients received flecainide and 40 procainamide as the first treatment. There were no significant clinical difference between the two groups. Procainamide ws given at a dose of 1 g infused over 30 min, and followed by an infusion of 2 mg.min-1 over 1 h. Flecainide was given at a dose of 1.5 mg.kg-1 over 15 min followed by an infusion of 1.5 mg.kg-1 over 1 h. Drug infusion was continued until maximal dose, intolerance or reversion to sinus rhythm. After 1 h of wash out, patients remaining in atrial fibrillation were started on the second drug. Left atrial size was measured by echo. Serum levels of drug and atrial size did not differ between patients who returned to sinus rhythm and those who remained in atrial fibrillation. Conversion to sinus rhythm was achieved in 37 (92%) of the 40 patients treated with flecainide and 25 (65%) of those treated with procainamide (P < 0.001). The time required for reversion to sinus rhythm was similar between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Fibrilación Atrial/tratamiento farmacológico , Electrocardiografía/efectos de los fármacos , Flecainida/uso terapéutico , Procainamida/uso terapéutico , Adulto , Anciano , Fibrilación Atrial/fisiopatología , Función del Atrio Izquierdo/efectos de los fármacos , Función del Atrio Izquierdo/fisiología , Ecocardiografía/efectos de los fármacos , Femenino , Flecainida/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Procainamida/efectos adversosRESUMEN
We comment the results with non pharmacological treatment in 23 patients (mean age 11 +/- 4 years) with multiple episodes of palpitations, most of them required intravenous drugs for interrupting it. Twenty-eight procedures were performed, 17 catheter ablation and 11 surgical interventions. The energy source employed for fulguration until 1990 was DC and since 1991 radiofrequency. The best results with catheter ablation were obtained with accessory pathways. Interruption was achieved in all patients after a mean of 1.2 sessions per patient, but it was definitive in only 72%. Most of the patients (81%) remained asymptomatic without antiarrhythmic drugs. Nine patients with accessory pathways underwent surgery interruption, it was achieved in all; only one patient had arrhythmia recurrence, due to a second pathway in a different localization. We could not ablate a ectopic atrial tachycardia, that underwent surgery. There was only one indication for surgery in a patient with ventricular tachycardia. Catheter ablation does not present technical problem in children and teenagers, different from adults. The presented results lead us to suppose that the indications for non pharmacological treatment in the young will become more common.